Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373672 · ClinicalTrials.gov registry record · Phase 4
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
A Phase 4 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00373672 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 58 participants.
The verdict
NCT00373672, a Phase 4 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked.
Interventions
- DRUG placebo
- DRUG armodafinil (Nuvigil)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373672
The ClinicalTrials.gov registry entry for NCT00373672 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00373672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373672 about?
NCT00373672 is a clinical study titled "Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder". This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested...
What is the current status of trial NCT00373672?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2006-08. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00373672?
The interventions under investigation include: placebo (DRUG), armodafinil (Nuvigil) (DRUG).
Who is sponsoring clinical trial NCT00373672?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.